RxDoctor Payments Data

Alan Barcomb, MD

Family Medicine · Oakfield, NYNPI 1548220775

Payments from drug & device makers

$1,268in general payments, 2019–2025

Across 86 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$358
  • AstraZeneca$159
  • Indivior Inc.$153
  • GSK$124
  • Boehringer Ingelheim$119
  • Pfizer$59
  • plus $296 from 12 others

What the payments were for

  • Food & beverage$1,262100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,268 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$31,789
Medicare patients
191
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$195,262
OzempicSemaglutide97$157,013
JardianceEmpagliflozin117$136,060
TrulicityDulaglutide39$64,415
JanuviaSitagliptin Phosphate38$60,918
FarxigaDapagliflozin Propanediol42$52,098
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$38,507
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$37,994
XareltoRivaroxaban40$35,333
Tresiba Flextouch U-200Insulin Degludec11$34,165
Lantus SolostarInsulin Glargine,hum.Rec.Anlog135$28,910
Synjardy XrEmpagliflozin/Metformin Hcl18$23,242
Janumet XrSitagliptin Phos/Metformin Hcl16$17,452
EntrestoSacubitril/Valsartan24$15,110
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl94$12,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$195,262190 claims
Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat$119$164,544146 claims
Novo NordiskOzempic, Fiasp$358$161,283112 claims
MerckJanuvia, Janumet Xr, Janumet, Belsomra$26$89,86776 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta, Shingrix$124$74,824153 claims
Lilly USA, LLCTrulicity$36$64,41539 claims
AstraZenecaFarxiga, Symbicort$159$55,74558 claims
Johnson & JohnsonXarelto$58$35,33340 claims
Indivior Inc.Suboxone$153$8,30512 claims
AbbVieSynthroid$11$4,17357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Oakfield

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →